Related Experiment Video

Updated: May 23, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

Comparative effectiveness analysis of anticoagulant strategies in a large observational database of percutaneous

Gregory R Wise1, Brian P Schwartz, Nathaniel Dittoe

  • 1Kettering Medical Center, Dayton, OH, USA.

Journal of Interventional Cardiology
|April 3, 2012
PubMed

Insights

Bivalirudin use in percutaneous coronary intervention (PCI) significantly reduces inpatient mortality and bleeding events. This anticoagulant strategy also offers substantial cost savings compared to other treatments.

Area of Science:

  • Cardiology
  • Pharmacology
  • Health Economics

Background:

  • Percutaneous coronary intervention (PCI) is a primary method for coronary revascularization.
  • Various anticoagulant strategies are employed during PCI.
  • Cost containment is a significant factor in modern healthcare.

Purpose of the Study:

  • To conduct a comparative effectiveness analysis of major anticoagulant strategies used in PCI.
  • To evaluate clinical outcomes and associated costs of different anticoagulant regimens.
  • To assess real-world effectiveness in a large observational database.

Main Methods:

  • Retrospective analysis of the Premier observational database.
  • Comparative effectiveness analysis of anticoagulant treatments.
  • Utilized multiple linear and logistic regression models to control for confounding factors.

Main Results:

  • Bivalirudin use was linked to a 41% reduction in inpatient mortality and a 44% reduction in bleeding compared to heparin plus glycoprotein IIb/IIIa inhibitor (GPI).
  • Bivalirudin monotherapy resulted in an average cost saving of $976 per case.
  • Similar improvements were observed between bivalirudin and heparin, while combined bivalirudin and GPI use diminished cost benefits.

Conclusions:

  • Bivalirudin demonstrates superior comparative effectiveness in PCI by improving clinical outcomes and reducing hospital costs.
  • This study is the first to report improved clinical outcomes alongside decreased costs for PCI anticoagulation.
  • Real-world data supports bivalirudin as an optimal anticoagulant strategy for PCI.
Abstract

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...